Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate

Robert Güerri-Fernández 1 2Elisabet Lerma-Chippirraz 1 2Ana Fernandez Marron 1Natalia García-Giralt 1Judit Villar-García 1Jade Soldado-Folgado 1Alicia González-Mena 1Marta Trenchs-Rodríguez 3Ana Guelar 1Adolfo Díez-Pérez 1 2Todd T Brown 4Hernando Knobel 1 2

AIDS. 2018 Apr 24;32(7):913-920. doi: 10.1097/QAD.0000000000001780.PMID: 29424785

DOI: 10.1097/QAD.0000000000001780

Objective: Bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is used to assess bone health in HIV patients. DXA measures the amount of mineral, but not other key aspects of bone strength such as bone microarchitecture or bone quality. Trabecular bone score (TBS) and in-vivo microindentation directly measure trabecular microarchitecture and bone tissue quality, respectively. The aim of this study is to measure bone strength properties using these techniques.

Results: Forty naive HIV patients who were going to start antiretroviral therapy (ART), a single pill treatment with elvitegravir/cobicistat, tenofovir disoproxil fumarate (TDF), emtricitavine (FTC) were included. A significant reduction in BMD at spine (-3.25%, P < 0.001) and in femoral neck (-3.82%, P = 0.016) between baseline and 48 weeks of treatment were found. Bone microarchitecture score at the spine, as measured by TBS, also significantly decreased from 1.357 (0.09) to 1.322 (0.09) (-2.5%, P = 0.011) between baseline to 48 weeks of treatment. Microindentation (BMSi) values were significantly higher than at baseline [89.04 (4.2) versus 86.07 (6.1); 3.49%, P < 0.001] after 48 weeks of TDF-based ART treatment, indicating improved bone material properties.

CONCLUSION: A significant decrease in BMD and TBS were observed after 1 year of TDF therapy. However, tissue quality significantly improved after 1 year of treatment, suggesting a recovery of bone material properties following the control of the infection despite the significant reduction of BMD. These techniques provide additional and necessary information to DXA about bone health in treated HIV patients, and because of its convenience and feasibility they could be routinely apply to assess bone in clinical practice.

Scroll to Top

This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy

This website uses cookies to enhance the user experience. By using this site you agree to our privacy policy